Abstract
Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy.
| Original language | English |
|---|---|
| Pages (from-to) | S61-S66 |
| Journal | Kidney International |
| Volume | 72 |
| Issue number | SUPPL. 106 |
| DOIs | |
| State | Published - Aug 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Diabetic complications
- Fibrosis
- Histone acetylation
- Histone deacetylase inhibitor
- Hsp90
- Reactive oxygen species
Fingerprint
Dive into the research topics of 'Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver